[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 47 of about 47
1. Nadal SR, Calore EE, Nadal LR, Horta SH, Manzione CR: [Anal cytology for screening of pre-neoplasic lesions]. Rev Assoc Med Bras (1992); 2007 Mar-Apr;53(2):147-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal cytology for screening of pre-neoplasic lesions].
  • [Transliterated title] Citologia anal para rastreamento de lesões pré-neoplásicas.
  • BACKGROUND: High grade intra-epithelial neoplasias (HAIN) are probable precursors of anal carcinoma, with association to high-risk types of Human Papillomavirus (HPV).
  • This progression could be related to severity of the dysplasia and, albeit not yet confirmed, treatment of these lesions would prevent the evolution to cancer.
  • The aim of this study was to evaluate if anal cytology, with a cytobrush, could be useful to screen clinic and pre-clinic lesions provoked by HPV.
  • METHODS: Brushes were used to obtain smears from the anal canal of 102 HIV-positive patients with proctologic complaints.
  • HPV infection was denied by 33 patients, 14 had treated anal warts in the past, 28 had condylomas in the anal verge, seven had internal clinical lesions and 20 had both internal and external condylomas.
  • One patient with HAIN, without a history of HPV infection in the past, presented an anal canal ulcer which at biopsy was diagnosed as invasive squamous-cell carcinoma.
  • CONCLUSION: Results suggest that cytology could be used to diagnose anal cancer precursors.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma in Situ / pathology. HIV Infections / virology. Papillomaviridae / isolation & purification. Papillomavirus Infections / pathology. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17568919.001).
  • [ISSN] 0104-4230
  • [Journal-full-title] Revista da Associação Médica Brasileira (1992)
  • [ISO-abbreviation] Rev Assoc Med Bras (1992)
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


2. Troicki F, Pappas A, Noone R, Denittis A: Radiation therapy of recurrent anal squamous cell carcinoma in-situ: a case report. J Med Case Rep; 2010;4:67

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy of recurrent anal squamous cell carcinoma in-situ: a case report.
  • INTRODUCTION: High-grade anal intraepithelial neoplasia, also referred to as anal squamous carcinoma in-situ, or Bowen's disease of the anus, make up less than 1% of all digestive system cancers in the United States.
  • The treatment of choice is surgical resection with anal mapping.
  • This can compromise the anal sphincter leading to leakage.
  • CASE PRESENTATION: An 84-year-old Caucasian woman presented with post-excisional persistent/recurrent squamous cell carcinoma in-situ.
  • The initial lesion measured 3 cm in diameter on the right lateral side of the anal margin.
  • A standard surgery consisting of wide local excision with anal mapping was performed.
  • Our patient recurred with a 1.2 x 0.8 cm lesion on the left anal verge extending to the anal canal.
  • A biopsy along with mapping was done, and 2 of the 17 mapping specimens were positive for carcinoma in-situ, one in the anal canal.
  • Due to the location of the positive anal mapping, and in order to prevent sphincter compromise on re-excision, our patient was offered definitive radiation therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Australas J Dermatol. 2006 May;47(2):120-3 [16637809.001]
  • [Cites] J Clin Virol. 2005 Mar;32 Suppl 1:S25-33 [15753009.001]
  • [Cites] Swiss Med Wkly. 2003 Jun 28;133(25-26):353-9 [12947531.001]
  • [Cites] Br J Surg. 1997 May;84(5):675-8 [9171763.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 7;87(11):796-802 [7791229.001]
  • [Cites] Urol Clin North Am. 1992 Feb;19(1):83-91 [1310549.001]
  • [Cites] Dis Colon Rectum. 1997 Nov;40(11):1286-93 [9369101.001]
  • (PMID = 20181236.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2841077
  •  go-up   go-down


3. Shehan J, Wang JF, Repertinger S, Sarma DP: Perianal squamous cell carcinoma in-situ: a report of two human papilloma virus-negative cases. Cases J; 2008;1(1):114
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perianal squamous cell carcinoma in-situ: a report of two human papilloma virus-negative cases.
  • We are reporting two cases of perianal squamous cell carcinoma in-situ, negative for high-risk (HR) and low-risk (LR) human papilloma viruses.
  • A brief review of anal and perianal squamous cell carcinoma and the role of HPV are presented.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] APMIS. 2007 Mar;115(3):195-203 [17367464.001]
  • [Cites] Dis Colon Rectum. 1999 Jul;42(7):945-51 [10411443.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):753-7 [9973228.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):61-4 [12085257.001]
  • [Cites] Sex Transm Dis. 1987 Jan-Mar;14(1):58-60 [3563833.001]
  • [Cites] JAMA. 1985 Jul 19;254(3):358 [4009857.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):180-9 [1311142.001]
  • (PMID = 18715505.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2527493
  •  go-up   go-down


Advertisement
4. Parés D, Mullerat J, Pera M: [Anal intraepithelial neoplasia]. Med Clin (Barc); 2006 Nov 18;127(19):749-55
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal intraepithelial neoplasia].
  • [Transliterated title] Neoplasia intraepitelial anal.
  • Human papillomavirus (HPV) is responsible for anal condylomata, anal intraepithelial neoplasia (AIN) and anal squamous cell carcinoma.
  • The groups at risk are mainly patients with infection with human immunodeficiency virus, immunossuppressed patients and patients affected by HPV related diseases (e.g., cervical cancer or anal condyloma).
  • Low grade AIN (AIN I) or in extensive lesions, follow-up is advised to determine the possible evolution to anal squamous cell carcinoma.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma in Situ / pathology
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / surgery. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17198654.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 58
  •  go-up   go-down


5. Li AH, Phanuphak N, Sahasrabuddhe VV, Chaithongwongwatthana S, Vermund SH, Jenkins CA, Shepherd BE, Teeratakulpisarn N, van der Lugt J, Avihingsanon A, Ruxrungtham K, Shikuma C, Phanuphak P, Ananworanich J: Anal squamous intraepithelial lesions among HIV positive and HIV negative men who have sex with men in Thailand. Sex Transm Infect; 2009 Dec;85(7):503-7
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal squamous intraepithelial lesions among HIV positive and HIV negative men who have sex with men in Thailand.
  • OBJECTIVES: To evaluate the prevalence and risk factors of anal squamous intraepithelial lesions (ASIL), the putative anal cancer precursor, in Asian HIV positive and HIV negative men who have sex with men (MSM).
  • METHODS: Men who underwent anal Pap smear reported clinical, sociodemographic and behavioural information collected through questionnaire and interview between January 2007 and April 2008.
  • Overall, 27% had abnormal anal cytology: 13.2% had atypical squamous cells of undetermined significance (ASC-US), 11.5% had low-grade squamous intraepithelial lesion (LSIL) and 2.3% had high-grade squamous intraepithelial lesion (HSIL).
  • Anal condyloma was detected in 22% of HIV positive and 16.1% (9/56) of HIV negative MSM (p = 0.5).
  • In HIV positive MSM, anal condyloma (OR 3.42, 95% CI 1.29 to 9.04; p = 0.01) was a significant risk factor for ASIL.
  • Highly active antiretroviral therapy use and CD4+ T cell count were not associated with ASIL.
  • Thus, as greater numbers of HIV positive MSM live longer due to increasing access to HAART worldwide, effective strategies to screen and manage anal precancerous lesions are needed.
  • [MeSH-major] Anus Neoplasms / epidemiology. Carcinoma in Situ / epidemiology. Carcinoma, Squamous Cell / epidemiology. HIV Seronegativity / physiology. HIV Seropositivity / epidemiology. Homosexuality, Male / statistics & numerical data

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Int J STD AIDS. 2008 Aug;19(8):529-32 [18663038.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2114-9 [11966386.001]
  • [Cites] Dis Colon Rectum. 2002 Apr;45(4):453-8 [12006924.001]
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):367-73 [12626913.001]
  • [Cites] Am J Epidemiol. 2003 Jun 1;157(11):966-72 [12777359.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Arch Sex Behav. 2004 Apr;33(2):137-47 [15146146.001]
  • [Cites] Clin Infect Dis. 2004 May 15;38(10):1490-2 [15156490.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] J Infect Dis. 2004 Nov 1;190(9):1685-91 [15478076.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] AIDS. 1993 Jan;7(1):43-9 [8382927.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] AIDS. 1995 Nov;9(11):1255-62 [8561979.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 15;14(5):415-22 [9170415.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):320-6 [9525432.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1757-65 [15541448.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):896-905 [15956651.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 Aug 11;55(31):844-8 [16902394.001]
  • [Cites] AIDS. 2007 Jul 11;21(11):1457-65 [17589192.001]
  • [Cites] Sex Transm Dis. 2008 Feb;35(2):197-202 [18216727.001]
  • [Cites] Sex Transm Dis. 2008 Aug;35(8):721-4 [18650771.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • (PMID = 19525263.001).
  • [ISSN] 1472-3263
  • [Journal-full-title] Sexually transmitted infections
  • [ISO-abbreviation] Sex Transm Infect
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / P30 AI050410; United States / NCRR NIH HHS / RR / TL1 RR024978
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS527353; NLM/ PMC3875384
  •  go-up   go-down


6. Joseph DA, Miller JW, Wu X, Chen VW, Morris CR, Goodman MT, Villalon-Gomez JM, Williams MA, Cress RD: Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer; 2008 Nov 15;113(10 Suppl):2892-900
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Understanding the burden of human papillomavirus-associated anal cancers in the US.
  • BACKGROUND: Anal cancer is an uncommon malignancy in the US; up to 93% of anal cancers are associated with human papillomavirus.
  • METHODS: Cases diagnosed between 1998 and 2003 from 39 population-based cancer registries were analyzed.
  • The following anal cancer histologies were included in the analysis: squamous cell, adenocarcinoma, and small cell/neuroendocrine carcinomas.
  • RESULTS: From 1998 through 2003, the annual age-adjusted invasive anal cancer incidence rate was 1.5 per 100,000 persons.
  • Squamous cell carcinoma (SCC) was the most common histology overall, accounting for 18,105 of 21,395 (84.6%) cases of anal cancer.
  • Incidence rates of anal SCC increased 2.6% per year on average.
  • The majority of SCC cases were diagnosed at the in situ or localized stage (58.1%).
  • CONCLUSIONS: Rates of anal SCC varied by sex, race, and ethnicity.
  • Continued surveillance and additional research are needed to assess the potential impact of the HPV vaccine on the anal cancer burden in the US.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1464-9 [10717631.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):311-20 [12556684.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1517-23; discussion 1523-4; author reply 1524 [14605572.001]
  • [Cites] Cancer Causes Control. 2003 Nov;14(9):837-46 [14682441.001]
  • [Cites] Lancet Oncol. 2004 Mar;5(3):149-57 [15003197.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] Gastroenterology. 1988 Jul;95(1):107-11 [2836255.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):180-9 [1311142.001]
  • [Cites] Am J Epidemiol. 1992 Jul 1;136(1):54-8 [1329500.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] Am J Epidemiol. 1994 Jul 1;140(1):12-9 [8017399.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Semin Cancer Biol. 1998 Aug;8(4):307-13 [9870037.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):753-7 [9973228.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 Oct 27;55(42):1145-8 [17065979.001]
  • [Cites] Stat Methods Med Res. 2006 Dec;15(6):547-69 [17260923.001]
  • [Cites] Lancet Oncol. 2007 Apr;8(4):311-6 [17395104.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):919-25 [17527081.001]
  • [Cites] Clin Microbiol Rev. 2007 Jul;20(3):478-88, table of contents [17630336.001]
  • [Cites] Sex Transm Infect. 2007 Jul;83(4):257-66 [17664359.001]
  • [Cites] Cancer Causes Control. 2007 Dec;18(10):1175-86 [17805982.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2841-54 [18980203.001]
  • [Cites] Dermatol Ther. 2005 Jan-Feb;18(1):67-76 [15842614.001]
  • [Cites] Dan Med Bull. 2002 Aug;49(3):194-209 [12238281.001]
  • (PMID = 18980293.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] None / None / / N01 PC035137; United States / NCCDPHP CDC HHS / DP / U50 DP424071; United States / NCI NIH HHS / PC / N01 PC035137; United States / NCCDPHP CDC HHS / DP / U50 DP424071-04
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS104103; NLM/ PMC2729501
  •  go-up   go-down


7. Darvishian F, Stier EA, Soslow RA, Lin O: Immunoreactivity of p16 in anal cytology specimens: histologic correlation. Cancer; 2006 Feb 25;108(1):66-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoreactivity of p16 in anal cytology specimens: histologic correlation.
  • BACKGROUND: Cytology has been proposed as a potential screening tool in the evaluation of squamous anorectal disease in view of the morphologic similarities between anal and cervical squamous lesions.
  • Due to potential diagnostic pitfalls in anal cytology, p16 overexpression in these specimens was studied.
  • RESULTS: Twenty-eight of the 43 cases demonstrated the presence of squamous cells immunoreactive for p16 in cytology specimens.
  • The p16-positive cells were identified in cases of low-grade squamous intraepithelial lesion (LSIL) (n = 3 cases), high-grade squamous intraepithelial lesion (HSIL) (n = 22 cases), and invasive squamous carcinoma (n = 1 case), and in 2 cases with negative follow-up biopsies.
  • No cell immunoreactive for p16 was found in 15 cases (5 benign cases and 10 cases with either LSIL or HSIL).
  • The sensitivity and specificity of p16 immunoreactivity in the detection of anal intraepithelial neoplasia or carcinoma were 72% and 71%, respectively.
  • CONCLUSIONS: The presence of p16 immunoreactivity is a good predictor of dysplasia in anal specimens.
  • [MeSH-major] Anus Neoplasms / pathology. Biomarkers, Tumor / analysis. Carcinoma in Situ / pathology. Neoplasms, Squamous Cell / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16404747.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


8. Garrett K, Kalady MF: Anal neoplasms. Surg Clin North Am; 2010 Feb;90(1):147-61, Table of Contents
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal neoplasms.
  • A variety of lesions comprise tumors of the anal canal, with carcinoma in situ and epidermoid cancers being the most common.
  • Less common anal neoplasms include adenocarcinoma, melanoma, gastrointestinal stromal cell tumors, neuroendocrine tumors, and Buschke-Lowenstein tumors.
  • In this article different tumors and management of each, including a brief review of local excision for rectal cancer, are discussed in turn.
  • [MeSH-minor] Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / pathology. Carcinoma, Verrucous / diagnosis. Carcinoma, Verrucous / pathology. Humans. Intestinal Mucosa / pathology. Neoplasm Recurrence, Local / surgery. Prognosis. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20109639.001).
  • [ISSN] 1558-3171
  • [Journal-full-title] The Surgical clinics of North America
  • [ISO-abbreviation] Surg. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 105
  •  go-up   go-down


9. Herat A, Whitfeld M, Hillman R: Anal intraepithelial neoplasia and anal cancer in dermatological practice. Australas J Dermatol; 2007 Aug;48(3):143-53; quiz 154-5
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal intraepithelial neoplasia and anal cancer in dermatological practice.
  • Anal intraepithelial neoplasia is considered to be a precursor lesion of invasive anal cancer.
  • Human papillomaviruses are considered to be an important aetiological agent in both anal intraepithelial neoplasia and anal cancer.
  • Dermatologists are likely to encounter these conditions among the differential diagnoses to be considered in high-risk patients presenting with perianal and anal lesions.
  • Anal cancer rates are also increasing among the HIV-infected and HIV-non-infected population.
  • The successful treatment of anal intraepithelial neoplasia may reduce the risk of subsequent development of anal cancer.
  • However, current therapies for anal intraepithelial neoplasia may be associated with treatment-related morbidity and are not well validated.
  • It is currently not proven that they reduce the likelihood of the development of anal cancer.
  • Nevertheless, screening for anal intraepithelial neoplasia is being advocated for high-risk groups and may become standard dermatological care for these patients.
  • In view of recent developments in the understanding of this condition, this article reviews the current understanding of anal intraepithelial neoplasia and its treatment from a dermatological perspective.
  • [MeSH-major] Anus Neoplasms. Carcinoma in Situ. Carcinoma, Squamous Cell. Papillomavirus Infections

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17680964.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 115
  •  go-up   go-down


10. Abbasakoor F, Boulos PB: Anal intraepithelial neoplasia. Br J Surg; 2005 Mar;92(3):277-90
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal intraepithelial neoplasia.
  • BACKGROUND: Anal intraepithelial neoplasia (AIN) is believed to be a precursor of anal squamous cell cancer and its incidence is rising in high-risk groups, particularly those infected with the human immunodeficiency virus (HIV).
  • The pathological processes involved in the progression of AIN are becoming clearer but the natural history, particularly the rate of progression to invasive cancer, remains unknown.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms. Carcinoma in Situ. Carcinoma, Squamous Cell

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 British Journal of Surgery Society Ltd.
  • (PMID = 15736144.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 131
  •  go-up   go-down


11. Scott H, Khoury J, Moore BA, Weissman S: Routine anal cytology screening for anal squamous intraepithelial lesions in an urban HIV clinic. Sex Transm Dis; 2008 Feb;35(2):197-202
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Routine anal cytology screening for anal squamous intraepithelial lesions in an urban HIV clinic.
  • OBJECTIVES: The purpose of this study is to describe our experience with routine anal cancer screening using anal cytology, determine risk factors for abnormal anal cytology, and determine if an association exists between cytology and histology in patients with HIV infection.
  • METHODS: Demographics, CD4+ T-cell count, STD history, and cytology and histology data were extracted from medical charts of patients seen between November 1, 2002, and November 30, 2004.
  • Multivariate analysis was conducted using logistic regression controlling for age, race, sex, CD4+ T-cell nadir, and HIV exposure category.
  • RESULTS: Overall, 276 of 560 of the clinic patients received a screening anal cytology during the study period.
  • Of these patients, 11 were excluded from the analysis and 74 of 265 (27.9%) patients screened had an abnormal anal cytology.
  • They were also more likely to have a lower CD4+ nadir (142 cells/mm3 vs. 223 cells/mm3, P = 0.005) and CD4+ at time of anal cytology (353 cells/mm3 vs. 497 cells/mm3, P <0.001).
  • Those with an abnormal anal cytology also had higher occurrence of anal disease on perianal visual inspection (30% vs. 9%, P <0.001) and were more likely to have a history of genital warts (23% vs. 12%, P = 0.02) or herpes (35% vs. 22%, P = 0.02).
  • Two patients had anal intraepithelial neoplasia (AIN) I, 2 AIN II, 3 AIN III, and 2 squamous cell carcinoma in situ on histology.
  • CONCLUSION: Routine anal cytology screening is a feasible tool to incorporate into HIV care for patients regardless of gender and HIV risk factors.
  • [MeSH-major] Anus Neoplasms / diagnosis. HIV Infections / complications. Neoplasms, Squamous Cell / pathology. Urban Health Services / organization & administration
  • [MeSH-minor] Adult. Aged. Anal Canal / pathology. Colonoscopy / methods. Female. Follow-Up Studies. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18216727.001).
  • [ISSN] 0148-5717
  • [Journal-full-title] Sexually transmitted diseases
  • [ISO-abbreviation] Sex Transm Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Abramowitz L, Benabderrahmane D, Ravaud P, Walker F, Rioux C, Jestin C, Bouvet E, Soulé JC, Leport C, Duval X: Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: prevalence and associated factors. AIDS; 2007 Jul 11;21(11):1457-65
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: prevalence and associated factors.
  • OBJECTIVE: To assess the prevalence of and factors associated with squamous intraepithelial lesions and condyloma [human papillomavirus (HPV)-related lesions) in HIV-infected patients.
  • RESULTS: Of 473 patients examined, (200 homosexual men, 123 heterosexual men, 150 women), 108 (23%) had histologically confirmed anal HPV-related lesions (36, 15 and 11% of the respective populations), including 51 (47%) with only endoanal localization.
  • Among these 108 patients, histological dysplasia of grades I or II and grade III were noted in 59 and two patients, respectively, invasive endoanal cancer in one; three patients also had high-risk oncogenicity HPV without dysplasia.
  • Independent identified associated factors of HPV-related condyloma were the number of incidents of sexual intercourse per month [odds ratio (OR) 1.04; 95% confidence interval (CI) 1.01-1.06], CD4 cell count below 200 x 10 cells/l (OR 3.22; 95% CI 1.37-7.60), history of anal HPV lesion (OR 4.57; 95% CI 2.13-9.81), and receptive anal intercourse (OR 2.30; 95% CI 1.11-4.77).
  • The two latter factors remained associated with histological dysplasia (OR 2.82; 95% CI 1.38-5.76 for history of anal condyloma, and OR 4.29; 95% CI 2.18-8.44 for receptive anal intercourse).
  • [MeSH-major] Anus Diseases / virology. Anus Neoplasms / virology. Carcinoma in Situ / virology. Condylomata Acuminata / diagnosis. HIV Infections / virology. Sexual Behavior
  • [MeSH-minor] Adult. Anal Canal / pathology. Anal Canal / virology. Cross-Sectional Studies. Female. Heterosexuality. Homosexuality. Humans. In Situ Hybridization. Male. Middle Aged. Odds Ratio. Papilloma / diagnosis. Papilloma / pathology. Papilloma / virology. Prevalence. Risk


13. Kreuter A, Brockmeyer NH, Wieland U: [Anal intraepithelial neoplasia and anal carcinoma: an increasing problem in HIV patients]. Hautarzt; 2010 Jan;61(1):21-6
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal intraepithelial neoplasia and anal carcinoma: an increasing problem in HIV patients].
  • Anal dysplasia is common in HIV patients, especially in HIV-positive men having sex with men (MSM).
  • High-grade anal dysplasia can progress to invasive anal cancer.
  • As in cervical carcinoma, there is a cause and effect relationship between anal cancer and human papillomavirus (HPV) infection, especially with high-risk types such as HPV16.
  • Several experts have recommended screening programs for anal cancer, including anal cytology along the lines of the Pap smear in women.
  • Clinical inspection, lesion biopsy, and treatment of anal dysplasia are performed under high-resolution anoscopy.
  • Anal cancer is divided into cancer of the anal margin and cancer of the anal canal.
  • Early cancer of the anal margin is excised akin to squamous cell cancer of the exposed skin, whereas cancer of the anal canal is treated by radiochemotherapy.
  • Physicians working in the field of HIV/AIDS should regularly screen their patients for the presence of anal dysplasia and anal cancer.
  • Basic diagnostic workup includes clinical inspection of the perianal area, digital rectal examination, and anal cytology.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / prevention & control. Carcinoma in Situ / virology. HIV Infections / complications. Precancerous Conditions / diagnosis. Precancerous Conditions / prevention & control

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2009 May 15;124(10):2375-83 [19189402.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):56-61 [18156992.001]
  • [Cites] J Am Acad Dermatol. 2005 Apr;52(4):603-8 [15793509.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] Br J Cancer. 1997;75(5):722-8 [9043031.001]
  • [Cites] J Invest Dermatol. 2008 Aug;128(8):2078-83 [18273049.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Int J STD AIDS. 2008 Feb;19(2):118-20 [18334066.001]
  • [Cites] Br J Surg. 1994 Apr;81(4):500-8 [8205420.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):355-73 [15137962.001]
  • [Cites] Arch Dermatol. 2006 Nov;142(11):1438-44 [17116834.001]
  • [Cites] Ann Intern Med. 2008 Sep 2;149(5):300-6 [18765699.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2120-9 [11966387.001]
  • [Cites] AIDS. 2007 Jul 11;21(11):1457-65 [17589192.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 Nov;6(11):925-34 [18410393.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] Curr Opin Infect Dis. 2009 Apr;22(2):109-14 [19276878.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] ANZ J Surg. 2006 Aug;76(8):715-7 [16916390.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] Int J Colorectal Dis. 2002 Jul;17(4):203-15 [12073068.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2550-7 [18427149.001]
  • [Cites] Lancet Oncol. 2004 Mar;5(3):149-57 [15003197.001]
  • [Cites] Curr Opin Oncol. 2009 Sep;21(5):433-8 [19587592.001]
  • (PMID = 19967333.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML: High resolution anoscopy in the planned staged treatment of anal squamous intraepithelial lesions in HIV-negative patients. J Gastrointest Surg; 2007 Nov;11(11):1410-5; discussion 1415-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High resolution anoscopy in the planned staged treatment of anal squamous intraepithelial lesions in HIV-negative patients.
  • Anal dysplasia (low-grade squamous intraepithelial lesions, LSIL; high-grade squamous intraepithelial lesions, HSIL) is a challenging disease for the surgeon.
  • We reviewed 42 patients that underwent high-resolution anoscopy (HRA)-targeted surgical therapy of anal dysplasia in the past 10 years.
  • Patients were followed up in the Anal Neoplasia Clinic with physical examination, cytology, HRA, and biopsy if indicated.
  • Progression to HSIL was seen in one patient with LSIL and to squamous cell carcinoma in one patient with HSIL despite therapy.
  • HRA-targeted surgical therapy coupled with surveillance and re-treatment with office-based therapies offered an effective method in controlling anal dysplasia in the immunocompetent patient.
  • Morbidity is minimal, and our progression to cancer rate is low (2.4%).
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma in Situ / surgery. Carcinoma, Squamous Cell / surgery

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17710507.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Eng C: Anal cancer: current and future methodology. Cancer Invest; 2006 Aug-Sep;24(5):535-44
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer: current and future methodology.
  • Despite the small number of patients affected by carcinoma of the anal canal it remains one of the most challenging cancers to treat.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Carcinoma in Situ / drug therapy. Carcinoma in Situ / pathology. Carcinoma in Situ / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / therapeutic use. Clinical Trials as Topic. Fluorouracil / therapeutic use. HIV Infections / complications. Humans. Mitomycin / therapeutic use. Neoadjuvant Therapy. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm, Residual. Papillomavirus Infections / complications

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16939964.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 64
  •  go-up   go-down


16. Kagawa R, Yamaguchi T, Furuta R: Histological features of human papilloma virus 16 and its association with the development and progression of anal squamous cell carcinoma. Surg Today; 2006;36(10):885-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological features of human papilloma virus 16 and its association with the development and progression of anal squamous cell carcinoma.
  • PURPOSE: To investigate the development of anal squamous cell carcinoma (SCC) and the expression patterns of human papillomavirus (HPV).
  • The expression patterns of HPV in the cancer cell nuclei was investigated by in situ hybridization (ISH) using HPV probes.
  • RESULTS: Amplification of DMD genes was confirmed in 8 of 20 patients with anal SCC, suggesting that tumor DNA was preserved in these patients.
  • In two patients with carcinoma in situ (CIS), the cancer cells showed only a diffuse pattern (DP), and in two patients with invasive cancer, the cancer cell showed only an oligo-dot pattern (OP).
  • In one patient with lesions ranging from CIS to invasive cancer, the histologic features varied in each area, from DP to OP.
  • CONCLUSIONS: These findings show that HPV16 infection is closely involved in the development of anal SCC and suggest that the change in the genome occurs at the stage of microinvasive cancer.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. DNA, Viral / genetics. Human papillomavirus 16 / genetics. Papillomavirus Infections / pathology
  • [MeSH-minor] Disease Progression. Female. Follow-Up Studies. Humans. In Situ Hybridization. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Front Biosci. 2002 Mar 01;7:e77-84 [11861218.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):61-4 [12085257.001]
  • [Cites] Science. 1990 Apr 6;248(4951):76-9 [2157286.001]
  • [Cites] Am J Surg Pathol. 1986 Jan;10(1):1-8 [3006523.001]
  • [Cites] Int J Cancer. 1990 Jul 15;46(1):8-11 [2163992.001]
  • [Cites] Nucleic Acids Res. 1988 Dec 9;16(23):11141-56 [3205741.001]
  • [Cites] Jpn J Cancer Res. 1991 May;82(5):524-31 [1648051.001]
  • [Cites] EMBO J. 1984 May;3(5):1151-7 [6329740.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Jun;80(12):3812-5 [6304740.001]
  • [Cites] J Clin Pathol. 1997 Aug;50(8):625-34 [9301544.001]
  • [Cites] World J Gastroenterol. 1998 Aug;4(4):298-302 [11819303.001]
  • [Cites] J Exp Clin Cancer Res. 1999 Mar;18(1):47-52 [10374676.001]
  • [Cites] Cancer. 1992 Oct 1;70(7):1967-73 [1326398.001]
  • [Cites] Ann Intern Med. 2003 Mar 18;138(6):453-9 [12639077.001]
  • [Cites] Int J Cancer. 1983 Nov 15;32(5):563-5 [6315601.001]
  • [Cites] Curr Opin Investig Drugs. 2004 Dec;5(12):1247-61 [15648945.001]
  • [Cites] Science. 1989 Feb 17;243(4893):934-7 [2537532.001]
  • [Cites] Obstet Gynecol. 2004 Oct;104(4):751-5 [15458897.001]
  • (PMID = 16998682.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


17. Buchs NC, Allal AS, Morel P, Gervaz P: Prevention, chemoradiation and surgery for anal cancer. Expert Rev Anticancer Ther; 2009 Apr;9(4):483-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention, chemoradiation and surgery for anal cancer.
  • Management of patients with squamous cell carcinoma of the anus (SCCA) has remained virtually unchanged since the 1980s.
  • By contrast, the demographics of SCCA are evolving, with the emergence of a high-risk group of patients: HIV-positive male homosexuals are prone to develop anal intra-epithelial neoplasia and rapidly progress towards invasive SCCA.
  • By many aspects, anal cancer is similar to uterine cervix cancer - a sexually transmitted disease driven by oncogenic human papillomavirus (HPV) infection.
  • [MeSH-major] Anus Neoplasms. Carcinoma, Squamous Cell
  • [MeSH-minor] Adolescent. Alphapapillomavirus / pathogenicity. Carcinoma in Situ / surgery. Carcinoma in Situ / virology. Combined Modality Therapy. Female. HIV Infections / complications. Homosexuality, Male. Humans. Male. Papillomavirus Infections / prevention & control. Papillomavirus Vaccines. Radiotherapy, Adjuvant / adverse effects. Salvage Therapy. Surgical Flaps. Surgical Wound Dehiscence / etiology. Surgical Wound Dehiscence / prevention & control. Vaccination

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • HIV InSite. treatment guidelines - HIV InSite .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19374601.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Number-of-references] 66
  •  go-up   go-down


18. Watson AJ, Smith BB, Whitehead MR, Sykes PH, Frizelle FA: Malignant progression of anal intra-epithelial neoplasia. ANZ J Surg; 2006 Aug;76(8):715-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant progression of anal intra-epithelial neoplasia.
  • BACKGROUND: Anal intra-epithelial neoplasia (AIN) is believed to be a precursor to squamous cell carcinoma of the anus.
  • The risk of developing anal cancer in patients with AIN, although known to occur, has been thought to be relatively low.
  • The patients at risk of developing squamous cell carcinoma were the immunocompromised and those with genital intra-epithelial field change.
  • [MeSH-major] Anus Neoplasms / epidemiology. Anus Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / epidemiology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16916390.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


19. Franceschi S, De Vuyst H: Human papillomavirus vaccines and anal carcinoma. Curr Opin HIV AIDS; 2009 Jan;4(1):57-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus vaccines and anal carcinoma.
  • PURPOSE OF REVIEW: To explore the possible role of current prophylactic vaccines against human papillomavirus (HPV) in the prevention of anal intraepithelial neoplasia and squamous cell carcinoma of the anus (SCCA).
  • In addition, more than 90% prevalence of HPV was found in anal intraepithelial neoplasia.
  • Answers to some still open questions, notably vaccine efficacy in men and HIV-infected individuals and willingness to expand vaccination programmes to both sexes, are essential to predict the ultimate impact of HPV vaccines on the prevention of cancerous and precancerous anal lesions.
  • [MeSH-major] Anus Neoplasms / prevention & control. Carcinoma in Situ / prevention & control. Carcinoma, Squamous Cell / prevention & control. HIV Infections / complications. Papillomavirus Infections / prevention & control. Papillomavirus Vaccines / therapeutic use

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19339940.001).
  • [ISSN] 1746-6318
  • [Journal-full-title] Current opinion in HIV and AIDS
  • [ISO-abbreviation] Curr Opin HIV AIDS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / Papillomavirus Vaccines
  • [Number-of-references] 56
  •  go-up   go-down


20. Chiao EY, Giordano TP, Palefsky JM, Tyring S, El Serag H: Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis; 2006 Jul 15;43(2):223-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review.
  • Individuals with human immunodeficiency virus (HIV) infection are at increased risk for human papillomavirus-related squamous cell cancer of the anus.
  • Screening HIV-infected patients for squamous cell cancer of the anus and human papillomavirus-related anal dysplasia may prevent excess morbidity and mortality.
  • We have conducted a systematic review of the indirect evidence in the literature regarding the utility of anal Papanicolau (Pap) smear screening of HIV-infected individuals in the highly active antiretroviral therapy era.
  • Although there are no published studies evaluating the efficacy of anal Pap smear screening for preventing squamous cell cancer of the anus or anal intraepithelial neoplasia, we reviewed data regarding the burden of disease, anal Pap smear sensitivity and specificity, the prevalence of anal dysplasia, and 1 cost effectiveness study.
  • The available evidence demonstrates that HIV-infected individuals have an increased risk for squamous cell cancer of the anus and anal intraepithelial neoplasia.
  • This review identifies important areas for further study before routine anal Pap smear screening can be recommended.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. HIV Infections / complications. Papanicolaou Test. Papillomavirus Infections / diagnosis. Precancerous Conditions / diagnosis. Vaginal Smears
  • [MeSH-minor] Antiretroviral Therapy, Highly Active. Carcinoma in Situ / diagnosis. Carcinoma in Situ / etiology. Female. Humans. Male. Mass Screening. Papillomaviridae


21. Tramujas da Costa e Silva I, de Lima Ferreira LC, Santos Gimenez F, Gonçalves Guimarães RA, Botinelly Fujimoto L, Barbosa Cabral CR, Venturim Mozzer R, de Souza Atala L: High-resolution anoscopy in the diagnosis of anal cancer precursor lesions in renal graft recipients. Ann Surg Oncol; 2008 May;15(5):1470-5
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution anoscopy in the diagnosis of anal cancer precursor lesions in renal graft recipients.
  • BACKGROUND: Renal graft recipients are one of the population groups known to be at high risk of developing anal cancer.
  • This study investigated the presence of subclinical anal squamous intraepithelial lesions and the diagnostic ability of high-resolution anoscopy in detecting these lesions in renal graft recipients followed-up in Manaus.
  • METHODS: In a cross-sectional study, 50 renal graft recipients were interviewed and submitted to high-resolution anoscopy with biopsies of acetowhite lesions or of the anal transition zone mucosa when acetowhitening was absent.
  • Considering the histopathological reports of the examined anal specimens as the gold standard, the diagnostic validation and precision measures of high-resolution anoscopy were calculated as well as the prevalence of anal squamous intraepithelial lesions in the studied population.
  • RESULTS: In 42 renal graft recipients with satisfactory histopathological readings, prevalence of anal squamous intraepithelial lesions or condyloma acuminatum (ASIL-ACU) was 23.81%.
  • CONCLUSIONS: With a prevalence of 23.81% of subclinical ASIL-ACU lesions, the studied renal graft recipients had all these lesions detected by high-resolution anoscopy, notwithstanding most anal transition zone acetowhitened biopsied areas did not reveal histopathological aspects of anal cancer precursor lesions or condyloma acuminatum.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / diagnosis. Carcinoma in Situ / diagnosis. Carcinoma, Squamous Cell / diagnosis. Kidney Transplantation

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18299937.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Salit IE, Lytwyn A, Raboud J, Sano M, Chong S, Diong C, Chapman W, Mahony JB, Tinmouth J: The role of cytology (Pap tests) and human papillomavirus testing in anal cancer screening. AIDS; 2010 Jun 1;24(9):1307-13
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of cytology (Pap tests) and human papillomavirus testing in anal cancer screening.
  • OBJECTIVE: To assess anal oncogenic human papillomavirus (HPV) and anal cytology as screening tests for detecting high-grade anal intraepithelial neoplasia (AIN 2+), as this is an immediate anal cancer precursor.
  • METHODS: We did concomitant anal cytology, anal HPV testing and HRA with directed biopsies without knowing the results of each intervention.
  • The main outcome measures were the sensitivity, specificity, negative predictive value and positive predictive value of anal cytology and oncogenic HPV for the detection of AIN 2+.
  • RESULTS: Cytology was abnormal in 67% of patients: high-grade squamous intraepithelial lesion, 12%; low-grade squamous intraepithelial lesion, 43% and atypical squamous cells of undetermined significance, 12%.
  • Test performance characteristics for the detection of AIN 2+ using any abnormality on anal cytology were: sensitivity 84%, specificity 39%, negative predictive value 88% and positive predictive value 31%; using oncogenic HPV: sensitivity 100%, specificity 16%, negative predictive value 100% and positive predictive value 28%.
  • CONCLUSION: Anal cytology and HPV detection have high sensitivity but low specificity for detecting AIN 2+.
  • HIV-positive men who have sex with men have a high prevalence of AIN 2+ and require high-resolution anoscopy for optimal detection of high-grade anal dysplasia.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / pathology. Cytodiagnosis / methods. Papillomavirus Infections / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adult. Anal Canal / cytology. Anal Canal / pathology. Biopsy. Cross-Sectional Studies. Early Detection of Cancer. Homosexuality, Male. Humans. Male. Middle Aged. Sensitivity and Specificity. Sexual Behavior. Specimen Handling

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20442633.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


23. Kreuter A, Brockmeyer NH, Hochdorfer B, Weissenborn SJ, Stücker M, Swoboda J, Altmeyer P, Pfister H, Wieland U: Clinical spectrum and virologic characteristics of anal intraepithelial neoplasia in HIV infection. J Am Acad Dermatol; 2005 Apr;52(4):603-8
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical spectrum and virologic characteristics of anal intraepithelial neoplasia in HIV infection.
  • BACKGROUND: Anal intraepithelial neoplasia (AIN) represents a precursor lesion of invasive squamous cell carcinoma with a clear association to high-risk human papillomavirus (HPV) types.
  • HIV infection is strongly associated with a higher prevalence of genital HPV infection, a higher incidence of AIN, and, consecutively, an increased risk for anal cancer.
  • OBJECTIVE: The aim of this study was to determine the clinical spectrum of AIN and lesional HPV colonization in a cohort of homosexual men who were HIV positive and had a history of receptive anal intercourse.
  • RESULTS: Of all patients, 86% had anal HPV infection at their first visit.
  • Standardized screening programs for anal cancer prevention and treatment protocols for AIN in patients infected with HIV must be implemented.
  • [MeSH-major] Anus Neoplasms / virology. Carcinoma in Situ / virology. HIV Seropositivity / complications. Papillomaviridae / isolation & purification

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15793509.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


24. Gagne SE, Jensen R, Polvi A, Da Costa M, Ginzinger D, Efird JT, Holly EA, Darragh T, Palefsky JM: High-resolution analysis of genomic alterations and human papillomavirus integration in anal intraepithelial neoplasia. J Acquir Immune Defic Syndr; 2005 Oct 1;40(2):182-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution analysis of genomic alterations and human papillomavirus integration in anal intraepithelial neoplasia.
  • Anal intraepithelial neoplasia (AIN) is the likely precursor to anal cancer.
  • AIN is associated with human papillomavirus (HPV) infection, and HPV-associated genomic instability may play an important role in the progression of squamous intraepithelial neoplasia to cancer.
  • HPV16 DNA integration or rearrangement correlated with CNAs in host cell DNA (P = 0.007).
  • [MeSH-major] Anus Neoplasms / virology. Carcinoma in Situ / virology. Genome, Viral. Papillomaviridae / physiology. Virus Integration

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16186736.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 5 M01-RR-00079; United States / NCI NIH HHS / CA / R01CA54053; United States / NCI NIH HHS / CA / U01 CA66529; United States / NCI NIH HHS / CA / U01 CA70019
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


25. Walts AE, Thomas P, Bose S: Anal cytology: is there a role for reflex HPV DNA testing? Diagn Cytopathol; 2005 Sep;33(3):152-6
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cytology: is there a role for reflex HPV DNA testing?
  • There is an increased incidence of anal squamous carcinoma and its precursor lesions (anal intraepithelial neoplasia [AIN]) among persons who engage in anal-receptive sex.
  • Analogous to cervical cancer screening, anal Papanicplaou (Pap) smears currently are used to screen these high-risk populations.
  • Human papilloma virus (HPV) has been implicated in anal carcinoma pathogenesis and this study was performed to assess the potential role of HPV DNA testing as an adjunct to anal cytology.
  • We correlated cytological diagnoses and HPV DNA (Digene Hybrid Capture [HC II] assay) in anal specimens collected in SurePath liquid medium from 118 patients; 54.8% of cases diagnosed as atypical squamous cells of undetermined significance (ASC-US) and 87.8% diagnosed as low-grade squamous intraepithelial lesion (LSIL) or above tested positive for high- risk HPV DNA (B+).
  • [MeSH-major] Anal Canal / virology. Anus Neoplasms / diagnosis. Carcinoma in Situ / diagnosis. Carcinoma, Squamous Cell / diagnosis. Papillomavirus Infections / diagnosis. Tumor Virus Infections / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16078257.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Viral
  •  go-up   go-down


26. Van Damme N, Deron P, Van Roy N, Demetter P, Bols A, Van Dorpe J, Baert F, Van Laethem JL, Speleman F, Pauwels P, Peeters M: Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer; 2010;10:189
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas.
  • BACKGROUND: With the availability of effective anti-EGFR therapies for various solid malignancies, such as non-cell small lung cancer, colorectal cancer and squamous cell carcinoma of the head and neck, the knowledge of EGFR and K-RAS status becomes clinically important.
  • The aim of this study was to analyse EGFR expression, EGFR gene copy number and EGFR and K-RAS mutations in two cohorts of squamous cell carcinomas, specifically anal canal and tonsil carcinomas.
  • METHODS: Formalin fixed, paraffin-embedded tissues from anal and tonsil carcinoma were used.
  • EGFR protein expression and EGFR gene copy number were analysed by means of immunohistochemistry and fluorescence in situ hybridisation.
  • RESULTS: EGFR immunoreactivity was present in 36/43 (83.7%) of anal canal and in 20/24 (83.3%) of tonsil squamous cell carcinomas.
  • EGFR amplification was absent in anal canal tumours (0/23), but could be identified in 4 of 24 tonsil tumours.From 38 anal canal specimens, 26 specimens were successfully analysed for exon 18, 30 for exon 19, 34 for exon 20 and 30 for exon 21.
  • CONCLUSION: EGFR mutations were absent from squamous cell carcinoma of the anus and tonsils, but EGFR protein expression was detected in the majority of the cases.
  • EGFR amplification was seen in tonsil but not in anal canal carcinomas.
  • In our investigated panel, only one mutation in the K-RAS gene of a tonsil squamous cell carcinoma was identified.
  • This indicates that EGFR and K-RAS mutation analysis is not useful as a screening test for sensitivity to anti-EGFR therapy in anal canal and tonsil squamous cell carcinoma.
  • [MeSH-major] Anus Neoplasms / genetics. Biomarkers, Tumor / genetics. Carcinoma, Squamous Cell / genetics. Proto-Oncogene Proteins / genetics. Receptor, Epidermal Growth Factor / genetics. Tonsillar Neoplasms / genetics. ras Proteins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / chemistry. Anal Canal / pathology. Base Sequence. Belgium. Cohort Studies. DNA Mutational Analysis. Exons. Female. Gene Amplification. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Molecular Sequence Data. Mutation. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Oncol. 2000 Jan;36(1):76-80 [10889924.001]
  • [Cites] Oncology. 2009;77(5):293-9 [19923868.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1201-8 [14993230.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] J Histochem Cytochem. 2004 Jul;52(7):893-901 [15208356.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Oncogene. 1990 Jul;5(7):1037-43 [2197591.001]
  • [Cites] J Pathol. 1990 Jun;161(2):99-103 [2199641.001]
  • [Cites] Laryngoscope. 1994 Nov;104(11 Pt 1):1337-47 [7968162.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2879-82 [15837736.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] Am J Clin Pathol. 2005 Jul;124(1):20-3 [15923158.001]
  • [Cites] Eur J Cancer. 2006 Jan;42(1):109-11 [16324836.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44 [16467097.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):3992-5 [16618717.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):942-9 [16648870.001]
  • [Cites] Semin Oncol. 2006 Aug;33(4):369-85 [16890793.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4170-6 [16943533.001]
  • [Cites] Eur J Cancer. 2007 Feb;43(3):520-6 [17224267.001]
  • [Cites] Oncologist. 2007 Jan;12(1):90-8 [17285735.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1658-64 [17470858.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2164-70 [17538160.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3230-7 [17664471.001]
  • [Cites] Tumour Biol. 2007;28(5):273-9 [17962724.001]
  • [Cites] Ann Oncol. 2008 Mar;19(3):508-15 [17998284.001]
  • [Cites] N Engl J Med. 2008 Mar 13;358(11):1160-74 [18337605.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] Cancer Sci. 2008 Jun;99(6):1180-7 [18422739.001]
  • [Cites] Lancet. 2008 May 17;371(9625):1695-709 [18486742.001]
  • [Cites] Head Neck. 2008 Aug;30(8):1040-4 [18528899.001]
  • [Cites] Cancer Sci. 2008 Aug;99(8):1589-94 [18754871.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1116-27 [18784101.001]
  • [Cites] Gynecol Oncol. 2008 Nov;111(2):289-97 [18768215.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Dec;65(1):197-9 [19727729.001]
  • [Cites] Hum Pathol. 2009 Nov;40(11):1517-27 [19716155.001]
  • [Cites] Gastroenterology. 2001 Mar;120(4):857-66 [11231940.001]
  • (PMID = 20459770.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC2887399
  •  go-up   go-down


27. Kreuter A, Potthoff A, Brockmeyer NH, Gambichler T, Swoboda J, Stücker M, Schmitt M, Pfister H, Wieland U, German Competence Network HIV/AIDS: Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany. Br J Dermatol; 2010 Jun;162(6):1269-77
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany.
  • BACKGROUND: Anal intraepithelial neoplasia (AIN), a human papillomavirus (HPV)-associated potential precursor lesion of anal cancer, is frequent among human immunodeficiency virus (HIV)-positive men who have sex with men (MSM).
  • There is a paucity of data published on the progression of high-grade AIN to invasive cancer as well as on clinical and virological characteristics comparing anal margin and anal canal carcinoma.
  • OBJECTIVES: To search for anal carcinoma and AIN in a large series of HIV-positive MSM, to assess treatment response of anal carcinoma, and to analyse lesional HPV spectrum of anal cancers.
  • METHODS: Detection of anal carcinoma and AIN was performed using cytology, high-resolution anoscopy, and histology in case of abnormal findings.
  • Additionally, HPV analyses for 36 high- and low-risk α-HPV types were performed in patients with anal carcinoma.
  • Of these, 116 (26·0%) patients had normal findings, 163 (36·5%) had low-grade AIN, 156 (35·0%) had high-grade AIN, and 11 (2·5%) had anal carcinoma as evidenced by the highest grade of cytology/histology.
  • Five patients with anal cancer, who had refused treatment of their precancerous lesions, had progressed from high-grade AIN to invasive cancer within a median time of 8·6 months.
  • All anal cancers carried high-risk α-HPV types.
  • All five squamous cell carcinomas (SCCs) of the anal canal were HPV16 positive.
  • In contrast, only one of the four anal margin SCCs were HPV16 positive (HPV31, HPV33 and HPV33 + HPV68 were found in the other three anal margin SCCs).
  • In contrast to the cancer biopsies, a broad spectrum of surface high- and low-risk HPV types was found in anal swabs of the patients.
  • Surgical excision resulted in long-term disease control of all anal margin carcinomas, whereas combined chemoradiotherapy in carcinomas of the anal canal was associated with high recurrence rates, high toxicity, and high mortality.
  • CONCLUSIONS: Anal carcinoma and AIN are frequent in HIV-positive men, even in patients participating in anal cancer prevention programmes.
  • High-grade dysplasia in these patients can progress to invasive cancer within a short period of time.
  • Anal margin carcinoma and anal canal carcinoma differ substantially in their lesional HPV spectrum, prognosis and treatment response.
  • [MeSH-major] Anus Neoplasms / virology. Carcinoma in Situ / virology. Carcinoma, Squamous Cell / virology. HIV Seropositivity / complications. Papillomaviridae / isolation & purification

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal Compilation © 2010 British Association of Dermatologists.
  • (PMID = 20184584.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00365729
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


28. Jeong DH, Kim HK, Prince AE, Lee DS, Kim YN, Han J, Kim KT: Plasma proteomic analysis of patients with squamous cell carcinoma of the uterine cervix. J Gynecol Oncol; 2008 Sep;19(3):173-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma proteomic analysis of patients with squamous cell carcinoma of the uterine cervix.
  • OBJECTIVE: To compare plasma protein expression between patients with squamous cell carcinoma (SCC) of the cervix and normal controls.
  • METHODS: Plasma samples from patients with benign gynecological disease (normal cervix, n=6) and cervical cancer (SCC, n=6) were subjected to plasma proteomic analysis using two dimensional gel electrophoresis (2-DE) and matrix-assisted laser desorption/ionization mass spectroscopy (MALDI-MS).
  • Immunoturbidimetric assay of a larger group confirmed the results of 2-DE and Western blotting, and showed that ceruloplasmin and complement C3 were significantly elevated in the plasma of SCC patients in comparison with controls and patients with carcinoma in situ (CIS) of the uterine cervix.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1992 May;140(5):1039-43 [1374587.001]
  • [Cites] Anal Biochem. 1992 May 15;203(1):173-9 [1524213.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Apr;83(8):2363-7 [3458201.001]
  • [Cites] J Trace Elem Med Biol. 2004;18(1):1-8 [15487757.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):311-26 [14718574.001]
  • [Cites] Biosci Biotechnol Biochem. 2003 Jul;67(7):1574-7 [12913303.001]
  • [Cites] Immunol Rev. 2001 Apr;180:35-48 [11414361.001]
  • [Cites] Anticancer Res. 2001 Jan-Feb;21(1B):629-32 [11299817.001]
  • [Cites] Cancer Lett. 2000 Nov 28;160(2):229-36 [11053653.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):1108-21 [10699902.001]
  • [Cites] Mol Immunol. 1999 Sep-Oct;36(13-14):929-39 [10698347.001]
  • [Cites] Pancreas. 2008 Jan;36(1):61-9 [18192883.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7370-9 [18094419.001]
  • [Cites] Electrophoresis. 2007 Jun;28(12):1989-96 [17503403.001]
  • [Cites] Clin Chim Acta. 2007 Feb;377(1-2):119-26 [17067565.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):299-310 [16924372.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):1216-24 [16803509.001]
  • [Cites] Proteomics. 2006 May;6(9):2865-73 [16586433.001]
  • [Cites] J Med Invest. 2006 Feb;53(1-2):20-8 [16537992.001]
  • [Cites] Proteomics. 2005 Nov;5(17):4581-8 [16240287.001]
  • [Cites] Proteomics. 2005 Oct;5(15):4034-45 [16152657.001]
  • [Cites] J Proteome Res. 2005 Jul-Aug;4(4):1073-85 [16083256.001]
  • [Cites] Adv Clin Chem. 2005;39:159-84 [16013671.001]
  • [Cites] J Proteome Res. 2005 May-Jun;4(3):889-99 [15952736.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4613-9 [15741220.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Br J Cancer. 2005 Mar 14;92(5):895-905 [15726105.001]
  • [Cites] Immunopharmacology. 1999 May;42(1-3):39-45 [10408364.001]
  • [Cites] Int Urol Nephrol. 1997;29(4):427-32 [9405999.001]
  • [Cites] Biotechnology (N Y). 1996 Jan;14(1):61-5 [9636313.001]
  • [Cites] Hum Pathol. 1996 Dec;27(12):1329-35 [8958307.001]
  • [Cites] Gut. 1996 Feb;38(2):248-53 [8801206.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):129-42 [8686736.001]
  • [Cites] JAMA. 1994 Jun 15;271(23):1866-9 [8196145.001]
  • [Cites] J Biol Chem. 1994 Jul 8;269(27):18149-54 [7517938.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2808-17 [7514955.001]
  • [Cites] J Biol Chem. 1994 Feb 25;269(8):5481-4 [7509788.001]
  • [Cites] Anticancer Res. 1994 Sep-Oct;14(5B):2201-3 [7840524.001]
  • [Cites] Cancer. 1993 Feb 15;71(4 Suppl):1406-12 [8381706.001]
  • (PMID = 19471570.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676467
  • [Keywords] NOTNLM ; MALDI-MS / Plasma proteins / Squamous cell carcinoma / Two dimensional gel electrophoresis / Uterine cervical cancer
  •  go-up   go-down


29. Driemel O, Escher N, Ernst G, Melle C, von Eggeling F: S100A8 cellular distribution in normal epithelium, hyperplasia, dysplasia and squamous cell carcinoma and its concentration in serum. Anal Quant Cytol Histol; 2010 Aug;32(4):219-24
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S100A8 cellular distribution in normal epithelium, hyperplasia, dysplasia and squamous cell carcinoma and its concentration in serum.
  • We analyzed its cellular distribution and its serum level in patients with squamous cell carcinoma and normal controls.
  • STUDY DESIGN: We investigated the histopathologic features by tissue microarrays (TMAs) including 8 normal, 66 hyperplastic and dysplastic and 26 oral squamous cell carcinoma (OSCC) tissue cores.
  • The strongest expression of S100A8 was found in severe dysplasias and carcinoma in situ.
  • The serum levels of S100A8 were marginally reduced in cancer patients.
  • CONCLUSION: The expression of S100A8 is helpful only in the transition from severe dysplastic tissue to cancer.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21434523.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calgranulin A
  •  go-up   go-down


30. Ulaş M, Neşşar G, Bostanoğlu A, Aydoğ G, Kayaalp C, Ozoğul Y, Seven C: Development of two cancers in the same patient after ileorectal and ileal pouch anal anastomosis for familial adenomatous polyposis. Med Princ Pract; 2006;15(1):83-6
Genetic Alliance. consumer health - Familial Polyposis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of two cancers in the same patient after ileorectal and ileal pouch anal anastomosis for familial adenomatous polyposis.
  • After 19 years, in situ adenocarcinoma was detected in the rectal stump.
  • Completion proctectomy, mucosectomy, and hand-sewn ileal pouch anal anastomosis with protective ileostomy were performed.
  • In 2002, a metachronous cancer was detected at the anastomosis and abdominoperineal resection of the pouch and end ileostomy were performed.
  • Later on, the perineum was excised locally because of cancer recurrence.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenomatous Polyposis Coli / surgery. Anal Canal / surgery. Carcinoma, Squamous Cell / diagnosis. Colonic Neoplasms / complications. Ileostomy

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16340235.001).
  • [ISSN] 1011-7571
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


31. Sundström K, Eloranta S, Sparén P, Arnheim Dahlström L, Gunnell A, Lindgren A, Palmgren J, Ploner A, Sanjeevi CB, Melbye M, Dillner J, Adami HO, Ylitalo N: Prospective study of human papillomavirus (HPV) types, HPV persistence, and risk of squamous cell carcinoma of the cervix. Cancer Epidemiol Biomarkers Prev; 2010 Oct;19(10):2469-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective study of human papillomavirus (HPV) types, HPV persistence, and risk of squamous cell carcinoma of the cervix.
  • BACKGROUND: The link between squamous cell cervical carcinoma and human papillomavirus (HPV) 16/18 is well established, but the magnitude of the risk association is uncertain and the importance of other high-risk HPV (HRHPV) types is unclear.
  • METHODS: In two prospective nested case-control series among women participating in cytologic screening in Sweden, we collected 2,772 cervical smears from 515 women with cancer in situ (CIS), 315 with invasive squamous cell carcinoma (SCC), and individually matched controls.
  • CONCLUSIONS: Our large population-based study provides quantification of risks for different HPV types and prospective evidence that non-16/18 HRHPV types increase the risk for future cervical cancer.
  • IMPACT: This study gives further insights into cervical cancer risk stratification with implications for HPV-based prevention strategies.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] N Engl J Med. 1999 Nov 25;341(22):1633-8 [10572150.001]
  • [Cites] BMJ. 2009;339:b2569 [19638649.001]
  • [Cites] Int J Cancer. 2002 Oct 1;101(4):371-4 [12209962.001]
  • [Cites] Eur J Cancer. 2004 May;40(7):1058-65 [15093583.001]
  • [Cites] Virology. 2004 Jun 20;324(1):17-27 [15183049.001]
  • [Cites] Biometrics. 1988 Jun;44(2):355-67 [3390504.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):134-41 [8261434.001]
  • [Cites] Br J Cancer. 1995 Aug;72(2):498-505 [7640239.001]
  • [Cites] Anal Quant Cytol Histol. 1995 Aug;17(4):221-9 [8526946.001]
  • [Cites] J Gen Virol. 1995 Apr;76 ( Pt 4):1057-62 [9049358.001]
  • [Cites] Hum Pathol. 1997 Aug;28(8):899-904 [9269825.001]
  • [Cites] J Gen Virol. 1999 Feb;80 ( Pt 2):391-8 [10073699.001]
  • [Cites] Int J Cancer. 1999 Mar 15;80(6):818-22 [10074912.001]
  • [Cites] Int J Cancer. 1999 Sep 24;83(1):34-7 [10449604.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Nat Rev Cancer. 2007 Jan;7(1):11-22 [17186016.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1928-43 [17494926.001]
  • [Cites] Lancet. 2007 Jun 2;369(9576):1861-8 [17544766.001]
  • [Cites] Br J Cancer. 2007 Jul 2;97(1):129-32 [17551490.001]
  • [Cites] J Natl Cancer Inst. 2008 Apr 2;100(7):492-501 [18364502.001]
  • [Cites] J Natl Cancer Inst. 2008 Apr 2;100(7):513-7 [18364507.001]
  • [Cites] Am J Epidemiol. 2008 Jul 15;168(2):123-37 [18483125.001]
  • [Cites] Vaccine. 2008 Aug 19;26 Suppl 10:K1-16 [18847553.001]
  • [Cites] J Clin Microbiol. 2009 Mar;47(3):541-6 [19144817.001]
  • [Cites] J Infect Dis. 2009 Apr 1;199(7):926-35 [19236279.001]
  • [Cites] N Engl J Med. 2009 Apr 2;360(14):1385-94 [19339719.001]
  • [Cites] Int J Gynecol Cancer. 2009 Jul;19(5):934-42 [19574788.001]
  • [Cites] Lancet. 2009 Jul 25;374(9686):301-14 [19586656.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6027-32 [11085523.001]
  • (PMID = 20671136.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA093378; United States / NCI NIH HHS / CA / R01 CA111720; United States / NCI NIH HHS / CA / 1R01CA093378-01A1; United States / NCI NIH HHS / CA / 5R01CA111720-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS231473; NLM/ PMC2952359
  •  go-up   go-down


32. Wang X, Zheng B, Zhang RR, Li S, Chen X, Mulvihill JJ, Lu X, Pang H, Liu H: Automated analysis of fluorescent in situ hybridization (FISH) labeled genetic biomarkers in assisting cervical cancer diagnosis. Technol Cancer Res Treat; 2010 Jun;9(3):231-42
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Automated analysis of fluorescent in situ hybridization (FISH) labeled genetic biomarkers in assisting cervical cancer diagnosis.
  • The numerical and/or structural deviation of some chromosomes (i.e., monosomy and _polysomy of chromosomes 3 and X) are routinely used as positive genetic biomarkers to diagnose cervical cancer and predict the disease progression.
  • Among the available diagnostic methods to analyze the aneusomy of chromosomes 3 and X, fluorescence in situ hybridization (FISH) technology has demonstrated significant advantages in assisting clinicians to more accurately detect and diagnose cervical carcinoma at an early stage, in particular for the women at a high risk for progression of low-grade and high-grade squamous intra-epithelium lesions (LSIL and HSIL).
  • The experimental results of four test cases showed high agreement of FISH analysis results between the automated scheme and the cytogeneticist's analysis including 92.7% to 98.7% agreement in cell segmentation and 4.4% to 11.0% difference in cell classification.
  • This preliminary study demonstrates the feasibility of potentially applying the automatic FISH analysis method to expedite the screening and detecting cervical cancer at an early stage.
  • [MeSH-major] Biomarkers, Tumor / analysis. In Situ Hybridization, Fluorescence / methods. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / genetics

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2000 Nov;164(5):1768-75 [11025767.001]
  • [Cites] Cytometry. 1997 May 1;28(1):1-10 [9136750.001]
  • [Cites] Int J Cancer. 2001 Feb 1;91(3):359-65 [11169960.001]
  • [Cites] J Natl Cancer Inst. 2002 Jun 5;94(11):852-4 [12048273.001]
  • [Cites] Diagn Cytopathol. 2003 Jun;28(6):301-7 [12768634.001]
  • [Cites] Cancer. 2003 Oct 25;99(5):310-5 [14579298.001]
  • [Cites] Anal Cell Pathol. 1997 May;13(3):137-46 [9223756.001]
  • [Cites] Cytometry. 1997 Aug 1;28(4):289-97 [9266748.001]
  • [Cites] Hum Genet. 1997 Oct;100(5-6):525-35 [9341866.001]
  • [Cites] Blood. 1998 May 1;91(9):3357-65 [9558393.001]
  • [Cites] Cytometry. 1999 Aug 1;36(4):279-93 [10404143.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):41-6 [10502423.001]
  • [Cites] Am J Pathol. 2005 Apr;166(4):1229-38 [15793301.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):716-23 [15981811.001]
  • [Cites] Cytometry A. 2005 Sep;67(1):18-26 [16082715.001]
  • [Cites] J Med Virol. 2006 Jan;78(1):117-24 [16299730.001]
  • [Cites] Cytometry A. 2006 Jun;69(6):506-14 [16646048.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3032-8 [16809727.001]
  • [Cites] J Pathol. 2006 Dec;210(4):412-9 [17054308.001]
  • [Cites] Technol Cancer Res Treat. 2008 Jun;7(3):161-74 [18473488.001]
  • [Cites] J Biomed Opt. 2009 Mar-Apr;14(2):021002 [19405715.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1624-9 [15196550.001]
  • [Cites] Pathol Oncol Res. 2004;10(3):142-8 [15448749.001]
  • [Cites] J Natl Cancer Inst. 1994 Jan 5;86(1):6-7 [8271287.001]
  • [Cites] Cytometry. 1996 Jun 1;24(2):158-66 [8725665.001]
  • [Cites] Cytometry. 2001 Feb 1;43(2):87-93 [11169572.001]
  • (PMID = 20441233.001).
  • [ISSN] 1533-0338
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA136700; United States / NCI NIH HHS / CA / R01 CA136700-01; United States / NCI NIH HHS / CA / CA136700
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS220245; NLM/ PMC2916642
  •  go-up   go-down


33. Foster KW, Liu Z, Nail CD, Li X, Fitzgerald TJ, Bailey SK, Frost AR, Louro ID, Townes TM, Paterson AJ, Kudlow JE, Lobo-Ruppert SM, Ruppert JM: Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia. Oncogene; 2005 Feb 24;24(9):1491-500
eagle-i research resources. PMID 15674344 (Special Collections) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia.
  • By 6 weeks, lesions exhibited nuclear KLF4 and other morphologic and molecular similarities to squamous cell carcinoma in situ. p53 determined the patch size sufficient to establish lesions, as induction in a mosaic pattern produced skin lesions only when p53 was deficient.
  • The results suggest that KLF4 can function in the nucleus to induce squamous epithelial dysplasia, and indicate roles for p53 and epithelial-mesenchymal signaling in these early neoplastic lesions.

  • COS Scholar Universe. author profiles.
  • Addgene Non-profit plasmid repository. clones/clone libraries - Get Article's Plasmids - Addgene (subscription/membership/fee required).
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - FVB.Cg-Tg(tetO-KLF4)32831Rup/Mmjax (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):26737-40 [11389134.001]
  • [Cites] Cancer Surv. 1998;32:69-113 [10489624.001]
  • [Cites] Curr Opin Cell Biol. 2001 Dec;13(6):778-84 [11698196.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):418-25 [11694875.001]
  • [Cites] N Engl J Med. 2001 Dec 27;345(26):1890-900 [11756581.001]
  • [Cites] Development. 2002 Jun;129(11):2619-28 [12015290.001]
  • [Cites] J Invest Dermatol. 2002 Jun;118(6):998-1002 [12060394.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S2-9 [11684435.001]
  • [Cites] Nucleic Acids Res. 1999 Dec 1;27(23):4562-9 [10556311.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] J Biol Chem. 2000 Jun 16;275(24):18391-8 [10749849.001]
  • [Cites] Nucleic Acids Res. 2000 Aug 1;28(15):2969-76 [10908361.001]
  • [Cites] J Biol Chem. 2000 Dec 1;275(48):37798-806 [10954723.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6488-95 [11103818.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5867-73 [12384550.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] J Biol Chem. 2003 Mar 28;278(13):11661-9 [12538588.001]
  • [Cites] Cancer Cell. 2003 Mar;3(3):203-5 [12676578.001]
  • [Cites] Development. 2003 Jun;130(12):2767-77 [12736219.001]
  • [Cites] Oncogene. 2003 May 29;22(22):3424-30 [12776194.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):763-70 [14644203.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Jan;286(1):G23-30 [12919939.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):383-91 [14667505.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):425-9 [14706334.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):395-402 [14724568.001]
  • [Cites] Cell. 2004 Jan 23;116(2):235-46 [14744434.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):311-6 [15093538.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2709-19 [15102675.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3815-24 [15173090.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] J Cell Sci. 1987 Oct;88 ( Pt 3):305-12 [3129440.001]
  • [Cites] Cancer Res. 1989 Jul 15;49(14):3713-21 [2660980.001]
  • [Cites] Cell Differ Dev. 1990 Apr;30(1):27-34 [2350734.001]
  • [Cites] Cell. 1990 Jun 15;61(6):1147-55 [2161707.001]
  • [Cites] Nature. 1991 Jul 25;352(6333):345-7 [1852210.001]
  • [Cites] Nature. 1992 Mar 19;356(6366):215-21 [1552940.001]
  • [Cites] Cell. 1993 Sep 10;74(5):813-22 [8374952.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4477-80 [8402617.001]
  • [Cites] J Virol. 1994 Jul;68(7):4358-68 [7515971.001]
  • [Cites] Nature. 1994 Dec 22-29;372(6508):773-6 [7997263.001]
  • [Cites] Nucleic Acids Res. 1995 May 25;23(10):1686-90 [7784172.001]
  • [Cites] Cancer Metastasis Rev. 1995 Jun;14(2):113-24 [7554029.001]
  • [Cites] Methods Enzymol. 1995;254:3-20 [8531694.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1621-5 [8658135.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] J Cell Biochem. 1995 Dec;59(4):463-72 [8749716.001]
  • [Cites] J Biol Chem. 1996 Aug 16;271(33):20009-17 [8702718.001]
  • [Cites] J Biol Chem. 1996 Dec 6;271(49):31384-90 [8940147.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14025-9 [8943054.001]
  • [Cites] Am J Pathol. 1996 Dec;149(6):1899-917 [8952526.001]
  • [Cites] Nature. 1997 Apr 24;386(6627):761, 763 [9126728.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1997;254(8):376-83 [9332893.001]
  • [Cites] FEBS Lett. 1997 Dec 15;419(2-3):239-43 [9428642.001]
  • [Cites] J Biol Chem. 1998 Apr 24;273(17):10747-54 [9553140.001]
  • [Cites] J Biol Chem. 1998 Jul 10;273(28):17917-25 [9651398.001]
  • [Cites] J Cell Biol. 1998 Oct 19;143(2):469-86 [9786956.001]
  • [Cites] J Cell Biochem Suppl. 1998;30-31:111-22 [9893262.001]
  • [Cites] Oncogene. 1999 Jun 17;18(24):3593-607 [10380881.001]
  • [Cites] Cell Growth Differ. 1999 Jun;10(6):423-34 [10392904.001]
  • [Cites] Nat Genet. 1999 Aug;22(4):356-60 [10431239.001]
  • [Cites] Nature. 2001 May 17;411(6835):349-54 [11357142.001]
  • (PMID = 15674344.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30CA13148; United States / NCI NIH HHS / CA / P50 CA089019; United States / NCI NIH HHS / CA / P30 CA013148; United States / NCI NIH HHS / CA / R01 CA094030; United States / NCI NIH HHS / CA / R29 CA065686; United States / NCI NIH HHS / CA / CA89019; United States / NCI NIH HHS / CA / R01 CA065686; United States / NCI NIH HHS / CA / CA65686; United States / NCI NIH HHS / CA / CA094030
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / GKLF protein; 0 / Kruppel-Like Transcription Factors; 0 / Transcription Factors; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ NIHMS7908; NLM/ PMC1361530
  •  go-up   go-down


34. Ortholan C, Ramaioli A, Peiffert D, Lusinchi A, Romestaing P, Chauveinc L, Touboul E, Peignaux K, Bruna A, de La Roche G, Lagrange JL, Alzieu C, Gerard JP: Anal canal carcinoma: early-stage tumors &lt; or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy. Int J Radiat Oncol Biol Phys; 2005 Jun 1;62(2):479-85
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy.
  • PURPOSE: To investigate the clinical history, management, and pattern of recurrence of very early-stage anal canal cancer in a French retrospective survey.
  • METHODS: The study group consisted of 69 patients with Stage Tis and T1 anal canal carcinoma < or =1 cm treated between 1990 and 2000 (12 were in situ, 57 invasive, 66 Stage N0, and 3 Stage N1).
  • Of the 69 patients, 66 received radiotherapy (RT) and 3 with in situ disease were treated by local excision alone without RT.
  • These small anal cancers could be treated by RT using a small volume and moderate dose (40-50 Gy for subclinical lesions and 50-60 Gy for T1).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / physiology. Carcinoma in Situ / pathology. Carcinoma in Situ / radiotherapy. Carcinoma in Situ / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / radiotherapy. Carcinoma, Transitional Cell / surgery. Chi-Square Distribution. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy Dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890590.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Dakir EL H, Feigenbaum L, Linnoila RI: Constitutive expression of human keratin 14 gene in mouse lung induces premalignant lesions and squamous differentiation. Carcinogenesis; 2008 Dec;29(12):2377-84
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Constitutive expression of human keratin 14 gene in mouse lung induces premalignant lesions and squamous differentiation.
  • Squamous cell carcinoma accounts for 20% of all human lung cancers and is strongly linked to cigarette smoking.
  • It develops through premalignant changes that are characterized by high levels of keratin 14 (K14) expression in the airway epithelium and evolve through basal cell hyperplasia, squamous metaplasia and dysplasia to carcinoma in situ and invasive carcinoma.
  • In order to explore the impact of K14 in the pulmonary epithelium that normally lacks both squamous differentiation and K14 expression, human keratin 14 gene hK14 was constitutively expressed in mouse airway progenitor cells using a mouse Clara cell specific 10 kDa protein (CC10) promoter.
  • While the lungs of CC10-hK14 transgenic mice developed normally, we detected increased expression of K14 and the molecular markers of squamous differentiation program such as involucrin, loricrin, small proline-rich protein 1A, transglutaminase 1 and cholesterol sulfotransferase 2B1.
  • Aging CC10-hK14 mice revealed multifocal airway cell hyperplasia, occasional squamous metaplasia and their lung tumors displayed evidence for multidirectional differentiation.
  • We conclude that constitutive expression of hK14 initiates squamous differentiation program in the mouse lung, but fails to promote squamous maturation.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Cell Biol. 1990 Dec;2(6):1028-35 [1712211.001]
  • [Cites] Cancer Res. 1990 Jan 1;50(1):120-8 [1967140.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1992;61(6):375-87 [1349777.001]
  • [Cites] J Natl Cancer Inst Monogr. 1992;(13):93-100 [1327037.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Nov 30;197(1):163-71 [7916613.001]
  • [Cites] J Biol Chem. 1995 Feb 10;270(6):2689-94 [7852338.001]
  • [Cites] Cell Growth Differ. 1997 Feb;8(2):145-55 [9040936.001]
  • [Cites] J Cell Biol. 1998 Oct 19;143(2):487-99 [9786957.001]
  • [Cites] Gene. 1998 Dec 11;224(1-2):59-66 [9931436.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2005 Apr;288(4):L625-32 [15579627.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):328-40 [15803139.001]
  • [Cites] Am J Respir Cell Mol Biol. 2005 Nov;33(5):455-62 [16055670.001]
  • [Cites] Curr Mol Med. 2007 Feb;7(1):3-14 [17311529.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Aug;322(2):529-40 [17496163.001]
  • [Cites] Nature. 2007 Aug 16;448(7155):807-10 [17676035.001]
  • [Cites] Annu Rev Pathol. 2006;1:331-48 [18039118.001]
  • [Cites] J Invest Dermatol. 2008 Jun;128(6):1517-24 [18049449.001]
  • [Cites] J Cell Biol. 2000 Apr 3;149(1):17-22 [10747083.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4005-9 [10945598.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13031-6 [11698679.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Transgenic Res. 2002 Feb;11(1):21-9 [11874100.001]
  • [Cites] Respir Res. 2002;3:20 [11980589.001]
  • [Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]
  • [Cites] Pathol Int. 2002 Apr;52(4):286-93 [12031084.001]
  • [Cites] Bioessays. 2002 Sep;24(9):789-800 [12210515.001]
  • [Cites] Am J Pathol. 2004 Feb;164(2):577-88 [14742263.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1647-54 [14996723.001]
  • [Cites] J Invest Dermatol. 2004 May;122(5):1207-13 [15140224.001]
  • [Cites] J Mol Biol. 1975 Nov 5;98(3):503-17 [1195397.001]
  • [Cites] Lab Invest. 1978 Jun;38(6):648-53 [661220.001]
  • [Cites] J Anat. 1981 Jan;132(Pt 1):71-84 [7275793.001]
  • [Cites] Cell. 1982 Nov;31(1):11-24 [6186379.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1984;45(2):221-40 [6143448.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Apr;81(7):1991-5 [6326095.001]
  • [Cites] Anal Biochem. 1984 Feb;137(1):266-7 [6329026.001]
  • [Cites] J Immunol. 1985 Oct;135(4):2589-92 [4031496.001]
  • [Cites] EMBO J. 1986 Jul;5(7):1567-75 [3017704.001]
  • [Cites] Cell. 1987 Feb 13;48(3):453-63 [2433047.001]
  • [Cites] Lab Invest. 1987 Aug;57(2):219-29 [3613528.001]
  • [Cites] J Invest Dermatol. 1989 Feb;92(2):203-9 [2465352.001]
  • [Cites] Mol Cell Biol. 1989 Sep;9(9):3685-97 [2476664.001]
  • [Cites] Am J Clin Pathol. 1992 Feb;97(2):233-43 [1372146.001]
  • (PMID = 18701433.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / KRT14 protein, human; 0 / Keratin-14
  • [Other-IDs] NLM/ PMC2639248
  •  go-up   go-down


36. Smeets SJ, Hesselink AT, Speel EJ, Haesevoets A, Snijders PJ, Pawlita M, Meijer CJ, Braakhuis BJ, Leemans CR, Brakenhoff RH: A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer; 2007 Dec 1;121(11):2465-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen.
  • Human papillomavirus type 16 (HPV16) plays a role in the development of a subgroup of head and neck squamous cell carcinomas (HNSCC).
  • We show that clinically meaningful viral HPV infections can be more reliably measured in FFPE HNSCC samples in a standard and high throughput manner, paving the way for prognostic and experimental vaccination studies, regarding not only HNSCC, but possibly also cancer types with HPV involvement in subgroups such as penile and anal cancer.
  • [MeSH-major] Algorithms. Carcinoma, Squamous Cell / virology. Head and Neck Neoplasms / virology. Human papillomavirus 16 / isolation & purification. Papillomavirus Infections / diagnosis. Tumor Virus Infections / diagnosis
  • [MeSH-minor] Adult. Aged. Biopsy / methods. DNA, Viral / isolation & purification. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Paraffin Embedding. Polymerase Chain Reaction. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Viral Load

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17680565.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


37. Savic S, Tapia C, Grilli B, Rufle A, Bihl MP, de Vito Barascud A, Herzog M, Terracciano L, Baty F, Bubendorf L: Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. Br J Cancer; 2008 Jan 15;98(1):154-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers.
  • Epidermal growth factor receptor (EGFR) gene mutations and increased copy numbers are considered as predictors of response to EGFR tyrosine kinase inhibitors (EGFR-TKI) in non-small-cell lung cancer (NSCLC).
  • Lung cancer diagnosis is often based on cytology alone.
  • Eighty-four cytological specimens from NSCLCs were prospectively analysed for EGFR gene mutation in exons 18-21 and EGFR gene copy numbers were evaluated by fluorescence in situ hybridisation (FISH).
  • Fluorescence in situ hybridisation results of cytological specimens were compared to the FISH results on matching biopsies (n=33).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Mutation / genetics. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Biopsy. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / secondary. Exons / genetics. Feasibility Studies. Female. Gene Dosage. Humans. In Situ Hybridization, Fluorescence. Male. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neuroectodermal Tumors / genetics. Neuroectodermal Tumors / metabolism. Neuroectodermal Tumors / secondary. Prospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2006 Feb 2;354(5):526-8; author reply 526-8 [16452569.001]
  • [Cites] Acta Cytol. 2005 Sep-Oct;49(5):471-6 [16334021.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Apr;58(1):31-45 [16531062.001]
  • [Cites] Mod Pathol. 2006 Apr;19(4):607-10 [16554736.001]
  • [Cites] J Eval Clin Pract. 2006 Apr;12(2):132-9 [16579821.001]
  • [Cites] Chest. 2006 Jun;129(6):1629-35 [16778285.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4409s-4415s [16857819.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6049-55 [17062680.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5034-42 [17075123.001]
  • [Cites] Lung Cancer. 2006 Dec;54(3):387-98 [17011067.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7232-41 [17189394.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1239-47 [17192902.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):587-95 [17290067.001]
  • [Cites] Anal Quant Cytol Histol. 2001 Apr;23(2):93-100 [11332084.001]
  • [Cites] Ann Oncol. 2002 Sep;13(9):1398-403 [12196365.001]
  • [Cites] Cell. 2002 Sep 20;110(6):669-72 [12297041.001]
  • [Cites] Eur Respir J. 2002 Oct;20(4):975-81 [12412692.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5 Suppl 14):3-9 [12422308.001]
  • [Cites] Chest. 2003 Jan;123(1 Suppl):129S-136S [12527572.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2237-46 [12748244.001]
  • [Cites] JAMA. 2003 Oct 22;290(16):2149-58 [14570950.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5813-24 [14676101.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1103-9 [15020612.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 4;96(15):1133-41 [15292385.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3238-47 [15310767.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8919-23 [15604253.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):857-65 [15681531.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1167-73 [15709185.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2106-10 [15788655.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2924-9 [15837743.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):133-44 [16014883.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5900-9 [16043828.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6838-45 [15998906.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8081-92 [16204011.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • (PMID = 18087280.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2359717
  •  go-up   go-down


38. Heselmeyer-Haddad K, Sommerfeld K, White NM, Chaudhri N, Morrison LE, Palanisamy N, Wang ZY, Auer G, Steinberg W, Ried T: Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer. Am J Pathol; 2005 Apr;166(4):1229-38
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer.
  • This provided the rationale for the development of a multicolor fluorescence in situ hybridization (FISH) probe set as a diagnostic tool for the direct detection of TERC gains in Pap smears.
  • We previously used this probe set to show that cervical intraepithelial neoplasia (CIN) 2 and CIN3 lesions could be distinguished from normal samples, atypical squamous cell of undetermined significance (ASCUS) and CIN1, with a sensitivity and specificity exceeding 90%, independent of the cytomorphological assessment.
  • The samples included CIN1/CIN2 lesions that progressed to CIN3 (progressors), CIN1/CIN2 lesions that regressed spontaneously (regressors), and normal Pap smears from women who subsequently developed CIN3 or cervical cancer.
  • [MeSH-minor] Adult. Disease Progression. Female. Humans. In Situ Hybridization, Fluorescence. Middle Aged. Papanicolaou Test. Retrospective Studies. Sensitivity and Specificity. Vaginal Smears


39. Nahas CS, Lin O, Weiser MR, Temple LK, Wong WD, Stier EA: Prevalence of perianal intraepithelial neoplasia in HIV-infected patients referred for high-resolution anoscopy. Dis Colon Rectum; 2006 Oct;49(10):1581-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients underwent anal canal and perianal high-resolution anoscopy in the office with biopsy of suspicious areas.
  • Office perianal biopsies diagnosed two patients with invasive squamous-cell carcinoma and nine with high-grade squamous intraepithelial lesion.
  • Seven of the nine patients with perianal high-grade squamous intraepithelial lesion on office biopsy were submitted to multiple biopsies under general anesthesia.
  • One of these seven had an occult perianal squamous-cell carcinoma.
  • CONCLUSIONS: Perianal disease was common in this group of HIV-infected patients; 11 patients (21 percent of total) were diagnosed with squamous-cell carcinoma or high-grade squamous intraepithelial lesion.
  • Our data suggest that anal canal neoplasia often is accompanied by perianal disease and illustrates the need for biopsy of any suspicious perianal lesions.
  • [MeSH-major] Anus Neoplasms / etiology. Carcinoma in Situ / etiology. Carcinoma, Squamous Cell / epidemiology. HIV Infections / complications. Proctoscopy / methods


40. Zawislak AA, Price JH, Dobbs SP, McClelland HR, McCluggage WG: the management of vulval intraepithelial neoplasia in Northern Ireland. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):780-5
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 52% of the cases, there was multifocal VIN, and in 43%, there was involvement of other sites such as the cervix, vagina, or anal region.
  • During the study period, 18 of 90 patients (20%) for whom follow-up was available developed invasive vulval squamous carcinoma.
  • Most of the vulval cancers were superficially invasive, but three patients died of vulval cancer during the study period.
  • [MeSH-major] Carcinoma in Situ / therapy. Carcinoma, Squamous Cell / therapy. Neoplasm Recurrence, Local / pathology. Vulvar Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681760.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


41. Theelen W, Speel EJ, Herfs M, Reijans M, Simons G, Meulemans EV, Baldewijns MM, Ramaekers FC, Somja J, Delvenne P, Hopman AH: Increase in viral load, viral integration, and gain of telomerase genes during uterine cervical carcinogenesis can be simultaneously assessed by the HPV 16/18 MLPA-assay. Am J Pathol; 2010 Oct;177(4):2022-33
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oncogenic human papillomavirus (HPV) infection is the most important risk factor in cervical carcinogenesis cases; high viral loads, viral integration into the host genome, and gain of the telomerase-related genes, TERT and TERC, are all factors associated with progression to cancer.
  • Validation was performed using quantitative PCR, the PapilloCheck and fluorescence in situ hybridization.
  • Only 5 out of 37 normal tissue samples or low-grade cervical lesions (ie, CIN1 and condyloma) showed either an HPV16 viral load higher than 25 copies per cell, viral integration, and/or gain of one of the telomerase-related genes, whereas for the high-grade cervical lesions, one or more of these risk factors was found in 25 of 30 cases.
  • Furthermore, the feasibility of the MLPA assay was shown for cytological samples, where in 57% of high-grade squamous intraepithelial lesion cases, the high-risk factors were detected using this assay.
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / etiology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / etiology. DNA, Viral / genetics. Feasibility Studies. Female. Humans. In Situ Hybridization, Fluorescence. Middle Aged. Nucleic Acid Amplification Techniques. Polymerase Chain Reaction. Uterus / metabolism. Uterus / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Fam Physician. 2006 Jan 1;73(1):105-12 [16417073.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Feb;157(1):42-8 [15676146.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/1-10 [16949995.001]
  • [Cites] J Pathol. 2006 Dec;210(4):412-9 [17054308.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):806-12 [17131311.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):17-22 [17220327.001]
  • [Cites] Gynecol Oncol. 2007 Sep;106(3):549-57 [17568661.001]
  • [Cites] J Clin Virol. 2007 Dec;40(4):321-4 [17981499.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):307-13 [18172324.001]
  • [Cites] Clin Biochem. 2008 Apr;41(6):423-8 [18206116.001]
  • [Cites] BMC Biotechnol. 2008;8:57 [18652663.001]
  • [Cites] J Clin Microbiol. 2008 Nov;46(11):3678-85 [18799702.001]
  • [Cites] Obstet Gynecol. 2008 Dec;112(6):1419-44 [19037054.001]
  • [Cites] Cytopathology. 2008 Dec;19(6):342-54 [19040546.001]
  • [Cites] Int J Cancer. 2009 Jan 15;124(2):381-6 [19003961.001]
  • [Cites] J Clin Microbiol. 2009 Feb;47(2):287-93 [19036939.001]
  • [Cites] J Natl Cancer Inst. 2009 Feb 4;101(3):153-61 [19176451.001]
  • [Cites] J Genet Genomics. 2009 Apr;36(4):257-65 [19376486.001]
  • [Cites] J Clin Virol. 2009 Jun;45(2):100-4 [19394266.001]
  • [Cites] J Obstet Gynaecol Res. 2009 Jun;35(3):503-6 [19527390.001]
  • [Cites] Int J Cancer. 2010 Feb 15;126(4):959-75 [19711394.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6132-6 [10626803.001]
  • [Cites] Proc Soc Exp Biol Med. 2000 Mar;223(3):316-21 [10719846.001]
  • [Cites] J Clin Microbiol. 2002 Mar;40(3):779-87 [11880393.001]
  • [Cites] J Clin Microbiol. 2002 Mar;40(3):886-91 [11880410.001]
  • [Cites] Nucleic Acids Res. 2002 Jun 15;30(12):e57 [12060695.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] J Clin Pathol. 2003 Jul;56(7):532-6 [12835300.001]
  • [Cites] Am J Pathol. 2003 Oct;163(4):1405-16 [14507648.001]
  • [Cites] J Pathol. 2004 Jan;202(1):23-33 [14694518.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):873-80 [14984955.001]
  • [Cites] Anal Biochem. 1984 Feb;137(1):221-6 [6731800.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):479-84 [8552665.001]
  • [Cites] J Clin Pathol. 1997 Jul;50(7):600-4 [9306943.001]
  • [Cites] Int J Cancer. 2006 Sep 1;119(5):1095-101 [16586444.001]
  • (PMID = 20813962.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  • [Other-IDs] NLM/ PMC2947296
  •  go-up   go-down


42. Walts AE, Bose S: BD ProEx C immunostaining in extramammary Paget's disease and perineal melanoma. Mod Pathol; 2009 Feb;22(2):246-51
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The differential diagnosis of perineal biopsies can include squamous intraepithelial lesions, extramammary Paget's disease, and melanoma.
  • BD ProEx C is a recently developed immunoassay that targets expression of two genes shown to be associated with cervical cancer.
  • Immunostaining for ProEx C has been validated in cervical cytology and positive staining has also been shown to be strongly associated with human papilloma virus (HPV)-induced cervical and anal intraepithelial neoplasia in biopsies.
  • In situ hybridization was negative for low-risk and high-risk HPV subtypes in all Paget and melanoma cases that were tested.
  • [MeSH-major] Antigens, Neoplasm / analysis. Anus Neoplasms / enzymology. Cell Cycle Proteins / analysis. DNA Topoisomerases, Type II / analysis. DNA-Binding Proteins / analysis. Melanoma / enzymology. Nuclear Proteins / analysis. Paget Disease, Extramammary / enzymology. Perineum / pathology. Reagent Kits, Diagnostic. Vaginal Neoplasms / enzymology. Vulvar Neoplasms / enzymology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alphapapillomavirus / genetics. Alphapapillomavirus / isolation & purification. Biopsy. DNA, Viral / isolation & purification. Diagnosis, Differential. Female. Humans. Immunoassay. In Situ Hybridization. Male. Middle Aged. Minichromosome Maintenance Complex Component 2. Mucous Membrane / enzymology. Mucous Membrane / pathology. Mucous Membrane / virology. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18931649.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cell Cycle Proteins; 0 / DNA, Viral; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Reagent Kits, Diagnostic; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


43. Guillaud M, Zhang L, Poh C, Rosin MP, MacAulay C: Potential use of quantitative tissue phenotype to predict malignant risk for oral premalignant lesions. Cancer Res; 2008 May 1;68(9):3099-107
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The importance of early diagnosis in improving mortality and morbidity rates of oral squamous cell carcinoma (SCC) has long been recognized.
  • We investigated the potential of quantitative tissue phenotype (QTP), measured by high-resolution image analysis, to identify severe dysplasia/carcinoma in situ (CIS; known to have an increased risk of progression) and to predict progression to cancer within hyperplasia or mild/moderate dysplasia.
  • There was a statistical difference between NPS of hyperplasia or mild/moderate dysplasia that progressed to cancer and those that did not.
  • In the multivariate Cox model, LOH and NPS together were the strongest predictors for cancer development.

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2488-92 [8653682.001]
  • [Cites] Nat Med. 1996 Jun;2(6):682-5 [8640560.001]
  • [Cites] Anal Cell Pathol. 1998;16(1):11-27 [9584897.001]
  • [Cites] J Pathol. 1998 Apr;184(4):360-8 [9664901.001]
  • [Cites] Oral Oncol. 1998 Mar;34(2):77-83 [9682768.001]
  • [Cites] Cytometry A. 2005;63(1):34-40 [15614828.001]
  • [Cites] Comput Methods Programs Biomed. 2005 Feb;77(2):99-113 [15652632.001]
  • [Cites] Oral Oncol. 2007 Mar;43(3):224-31 [16931119.001]
  • [Cites] Cell Oncol. 2007;29(1):47-58 [17429141.001]
  • [Cites] Ann N Y Acad Sci. 2007 Mar;1098:167-83 [17332080.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1087-94 [10613341.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):357-62 [10690511.001]
  • [Cites] J Pathol. 2000 Mar;190(4):462-9 [10699996.001]
  • [Cites] N Engl J Med. 2001 Apr 26;344(17):1323-6 [11320393.001]
  • [Cites] J Cell Biochem Suppl. 2000;Suppl 35:151-7 [11389545.001]
  • [Cites] Anal Cell Pathol. 2001;23(2):89-95 [11904464.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):210-9 [11990857.001]
  • [Cites] Int J Oral Maxillofac Surg. 2002 Apr;31(2):145-53 [12102411.001]
  • [Cites] Anal Cell Pathol. 2003;25(1):1-36 [12590175.001]
  • [Cites] Anal Cell Pathol. 2003;25(3):129-38 [12775917.001]
  • [Cites] Int J Oncol. 2003 Dec;23(6):1607-13 [14612933.001]
  • [Cites] Head Neck. 2004 Apr;26(4):345-52 [15054738.001]
  • [Cites] Cytometry A. 2004 Jul;60(1):81-9 [15229860.001]
  • [Cites] Nat Rev Cancer. 2004 Sep;4(9):677-87 [15343274.001]
  • [Cites] Cell Oncol. 2004;26(3):101-17 [15371646.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1972 Mar;33(3):389-99 [4501168.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):563-8 [6537892.001]
  • [Cites] Int J Oral Maxillofac Surg. 1987 Dec;16(6):656-64 [3125262.001]
  • [Cites] Anal Quant Cytol Histol. 1990 Jun;12(3):165-71 [2369469.001]
  • [Cites] J Oral Pathol Med. 1995 May;24(5):198-200 [7616457.001]
  • [Cites] Pathologica. 1995 Jun;87(3):286-99 [8570289.001]
  • (PMID = 18451134.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / R01 DE13124; United States / NIDCR NIH HHS / DE / DE017013-03; United States / NIDCR NIH HHS / DE / R01 DE017013-03; United States / NIDCR NIH HHS / DE / R01 DE013124; United States / NIDCR NIH HHS / DE / R01 DE017013
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS49511; NLM/ PMC2693059
  •  go-up   go-down


44. Raica M, Cimpean AM, Ribatti D: Angiogenesis in pre-malignant conditions. Eur J Cancer; 2009 Jul;45(11):1924-34
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MVD was found to be significantly increased in a relatively large spectrum of pre-malignant squamous cell lesions, such as in the oral mucosa, skin, uterine cervix, vulva and anal canal.
  • Additional evidences came from pre-malignant lesions of glandular epithelia, in which the angiogenic switch was demonstrated by the immunohistochemical expression of VEGF in gastric metaplasia and dysplasia, in atypical adenoma of the colon, atypical hyperplasia and carcinoma in situ of the breast and others.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19406633.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / Biomarkers; 0 / Ki-67 Antigen; 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 93
  •  go-up   go-down


45. Dahlström LA, Ylitalo N, Sundström K, Palmgren J, Ploner A, Eloranta S, Sanjeevi CB, Andersson S, Rohan T, Dillner J, Adami HO, Sparén P: Prospective study of human papillomavirus and risk of cervical adenocarcinoma. Int J Cancer; 2010 Oct 15;127(8):1923-30
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Such evidence is available for squamous cell carcinoma, but not for cervical adenocarcinoma.
  • Baseline smears from women who developed adenocarcinoma during follow-up (118 women with in situ disease and 164 with invasive disease) and their individually matched controls (1,434 smears) were analyzed for HPV using PCR.
  • Being positive for HPV 16 in the first cytologically normal smear was associated with increased risks for both future adenocarcinoma in situ (OR: 11.0, 95% CI: 2.6-46.8) and invasive adenocarcinoma (OR: 16.0, 95% CI: 3.8-66.7), compared to being negative for HPV 16.
  • Similarly, an HPV 18 positive smear was associated with increased risks for adenocarcinoma in situ (OR: 26.0, 95% CI: 3.5-192) and invasive adenocarcinoma (OR: 28.0, 95% CI: 3.8-206), compared to an HPV 18 negative smear.
  • Being positive for HPV 16/18 in 2 subsequent smears was associated with an infinite risk of both in situ and invasive adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2005 Nov 28;93(11):1301-4 [16265348.001]
  • [Cites] Int J Cancer. 2000 May 1;86(3):429-35 [10760834.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):303-15 [16507827.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):1025-31 [16803480.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):885-91 [17131323.001]
  • [Cites] J Natl Cancer Inst. 2008 May 7;100(9):622-9 [18445828.001]
  • [Cites] J Clin Microbiol. 2009 Mar;47(3):541-6 [19144817.001]
  • [Cites] Int J Cancer. 2009 Aug 1;125(3):525-9 [19449379.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1055-62 [11021808.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6027-32 [11085523.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(2):246-50 [11166153.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):63-73 [12556961.001]
  • [Cites] J Pathol. 2003 Dec;201(4):535-43 [14648656.001]
  • [Cites] Biometrics. 1988 Jun;44(2):355-67 [3390504.001]
  • [Cites] Br J Cancer. 1995 Aug;72(2):498-505 [7640239.001]
  • [Cites] Anal Quant Cytol Histol. 1995 Aug;17(4):221-9 [8526946.001]
  • [Cites] J Gen Virol. 1995 Apr;76 ( Pt 4):1057-62 [9049358.001]
  • [Cites] Cancer Causes Control. 1997 Sep;8(5):755-63 [9328198.001]
  • [Cites] Int J Cancer. 1998 Feb 9;75(4):536-45 [9466653.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):159-66 [10487628.001]
  • [Cites] Cancer Detect Prev. 2004;28(6):461-4 [15582270.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2191-9 [16172231.001]
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):171-5 [16404371.001]
  • (PMID = 20473898.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA093378-01A1; United States / NCI NIH HHS / CA / R01 CA093378-01A1; United States / NCI NIH HHS / CA / R01 CA111720-01; United States / NCI NIH HHS / CA / CA111720-02; United States / NCI NIH HHS / CA / CA111720-01; United States / NCI NIH HHS / CA / 1R01CA93378-01A1; United States / NCI NIH HHS / CA / R01CA111720-02; United States / NCI NIH HHS / CA / R01 CA111720-02; United States / NCI NIH HHS / CA / R01 CA093378; United States / NCI NIH HHS / CA / R01CA111720-01; United States / NCI NIH HHS / CA / 5R01CA111720-03; United States / NCI NIH HHS / CA / R01 CA111720-03; United States / NCI NIH HHS / CA / R01 CA111720; United States / NCI NIH HHS / CA / CA111720-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ NIHMS207185; NLM/ PMC2930102
  •  go-up   go-down


46. Cheng L, Bostwick DG: Overdiagnosis of bladder carcinoma. Anal Quant Cytol Histol; 2008 Oct;30(5):261-4
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To describe a group of archival patients who were overdiagnosed with bladder cancer according to contemporary criteria.
  • STUDY DESIGN: The study group consisted of 27 over-diagnosed patients who were identified upon review of a consecutive series of well-differentiated urothelial carcinomas (grade 1 transitional cell carcinoma) diagnosed between 1958 and 1963.
  • Findings overdiagnosed as malignancy included urothelial papilloma (9 patients), inverted papilloma (5), exuberant von Brunn's nest proliferation (hyperplasia) (5), papillary and polypoid cystitis (4), papillary urothelial hyperplasia (2), squamous papilloma (1) and endocervicosis (1).
  • During a mean followup of 12.2 years, 1 patient developed carcinoma in situ 11 years after diagnosis, and 1 was diagnosed with noninvasive low-grade urothelial carcinoma 5 years after diagnosis.
  • Awareness of these cancer mimics is critical to avoid overdiagnosis of bladder cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18980157.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Oono Y, Fu K, Nakamura H, Iriguchi Y, Yamamura A, Kishi D, Oda J, Ikematsu H, Mizutani M, Takayanagi S, Tomino Y: Narrowband imaging colonoscopy with a transparent hood for diagnosis of a squamous cell carcinoma in situ in the anal canal. Endoscopy; 2010;42 Suppl 2:E183-4
MedlinePlus Health Information. consumer health - Colonoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Narrowband imaging colonoscopy with a transparent hood for diagnosis of a squamous cell carcinoma in situ in the anal canal.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. Colonoscopy / methods

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20640982.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement